Dr. Samir Hanash, Program Head at the Fred Hutchinson Cancer Research Center in Seattle, WA will give the keynote address on the discovery and development of biomarkers at the 2nd annual Oncology Biomarkers Conference on January 19-20, 2009 in Miami, Florida.
Dr. Hanash will present on findings from studies of epithelial cancers, particularly lung and pancreatic cancer, which have transitioned from discovery to validation in pre-diagnostic sera that reveal the influence of current proteomics strategies to yield markers for early cancer detection.
Dr. Hanash will also discuss proteomic strategies that deliver biomarkers as well as the need for rigor with experimental design. He will cover case studies in the field that brought forth successful end results. Lastly, he will assess the future of oncology biomarker detection and validation.
GTCbio's 2nd Oncology Biomarkers conference on January 19-20, 2009 in Miami, FL will provide an extensive look at new and innovative techniques for discovering and validating biomarkers. Challenges to biomarker validation will be examined in depth, including regulatory perspectives on development and qualification and reimbursement strategies, as wll the clinical application of oncology biomarkers and enabling biomarkers in cancer drug development. Sign up now as space is limited! For more information visit gtcbio/conferenceDetails.aspx?id=142.
ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Source:
GTCBIO
434 W. Foothill Blvd. Monrovia,
CA 91016
Tel: (626) 256-6405
fax: (626) 256-6460
email: infogtcbiogtcbio
Комментариев нет:
Отправить комментарий